Security of supply of medical isotopes A pathway towards Full Cost Recovery
|
|
- Stephany Opal Reynolds
- 6 years ago
- Views:
Transcription
1 Security of supply of medical isotopes A pathway towards Full Cost Recovery Picture source: Book - Medical isotope production without highly enriched uranium (2009)
2 Aiming for Full Cost Recovery (FCR): an odd objective An economist would say It s not only about recovering your costs Producer surplus Commercial players would want to see a return on investment, based on the risk taken Return for risk And even maximise producer surplus based on the willingness to pay Willingness to pay Variable cost Keynes, An economist So maximise profit in order to attract private capital, invest in new capacity and innovation Price Fixed cost 2
3 Historically, governments had good reasons for supporting the development, construction and operation of nuclear (research) facilities Ownership structure of current research reactors used to produce Capacity in 6-day Curie 99Mo in 2022 Name: HFR Exp. Cap: Owner: EC Name: BR2 Exp. Cap: Owner: SKC-CEN Name: LVR-15 Exp. Cap: Owner: CVR Name: RA-3 Exp. Cap: Owner: CNEA 99Mo1) Name: RIAR & KARPOV Exp. Cap: Owner: RIAR Demand and supply curve for nuclear research Price Demand Supply gap due to market failure that is covered by governments Supply Name: MARIA Exp. Cap: Owner: NCBJ Name: SAFARI-1 Exp. Cap: Owner: NECSA Qmarket Name: OPAL Exp. Cap: Owner: ANTSO Fully Public owned Indirectly Public owned HFR is owned by EC, while OPAL, MARIA, SAFARI-1 & RA-3 are owned by national governments directly (e.g. through government agencies) LVR-15, BR-2, RIAR & KARPOV are owned by independent research institutes that are indirectly controlled by the government Qoptimum Quantity 1957 Euratom treaty: jointly develop nuclear activitites - health protection - safeguarding against proliferation of nuclear weapons - supply of nuclear fuel and - nuclear research Nuclear research as a public good (nonexcludable and non-rivalrous good), not being delivered by the market 1) This overview excludes Brazil, Korea, China and Russia due to their limited production (below < Ci-EOP / year) Source: Strategy& analysis 3
4 In the near future, we need to replace old reactors. Full Cost Recovery (FCR) is considered to be the key in order to achieve this To create a sustainable 99 Mo/ 99m Tc market, the High-Level Group on the Security of Supply of Medical Radioisotopes agreed upon six principles to realize longterm, secure 99 Mo/ 99m Tc supply A key principle is the move to Full Cost Recovery Full-cost Recovery is not a price-setting tool, but rather a methodology to define cost elements and allocation methods to determine the cost associated with 99 Mo/ 99m Tc production Source: Strategy& analysis based on OECD-NEA data, OECD-NEA updates, EANM OECD-NEA recommends 35% Outage Reserve Capacity (ORC) as buffer for unplanned reactor outages, to avoid potential global shortage crisis 4
5 An economic analysis of the 99 Mo supply chain is needed in order to determine how FCR can be stimulated Does not apply Applies Hospitals & end-users Radiopharmacies Generator Manufacturers Processors Research Reactors Target suppliers The good Perishable Same day days 2 days 1 day 6/7 days No Homogenous Yes generators are identical Yes, Bulk Moly No, Targets for specific processors Externalities The market Diagnostic scans patients + Better health Provides 99 TC dose - Safety Generators to produce 99 TC Extracts 99 Mo from targets Irradiates Mo targets Provides targets - Safety - Waste, safety and - Waste, safety and security security - Security Players Major Many Thousands 6 major Can be 4 Can be 5 players 4 integrated integrated Geographical Local Local Global Global Local Local Asset heavy Subsidised Asset light Long investment cycles (technology and licencing) 5
6 SubSub You need to move together in order to achieve FCR. If we keep on subsidizing current capacity, the market functions inefficiently Scenario 1: governments keep on subsidising current capacity Subsidies cause changes in the supply curve Supply curve FCR based pricing Price ( /six-day curie) P FCR Supply curve with subsidies Price ( /six-day curie) P S Sub Demand for 99 Mo R 1 R 2 R 3 R 4 Quantity (six-day curie) What if: all current supply is subsidised? Demand for 99 Mo Sub Sub R 1 R 2 R 3 R4 Quantity (six-day curie) leading to inefficient market outcomes Demand and supply curve 99 Mo Price ( /six-day curie) # P FCR P Q FCR Q S Specific subsidies as well as cross subsidies FCR based supply curve Subsidized supply curve Quantity (six-day curie) Note: The supply curves in these figures are meant for illustrative purposes only, as they do not take into account Fixed costs Welfare loss Prices remain low because of subsidies Lower prices lead to overconsumption, no incentive to use the good efficiently Overconsumption leads to more nuclear waste Transfer of welfare Tax payers pay for the subsidies provided by governments in countries with reactors Healthcare consumers in other countries benefit from subsidies No incentive new cap. As prices remain low, new capacity is struggling to ensure a viable business case with private funding 6
7 We need to address two problems in order to move towards FCR 1 Free rider problem 2 Price absorption problem A level playing field (between competitors) should be safeguarded by removing subsidies Price increase must be accepted/absorbed within the supply chain Pictures courtesy: Nounproject.com 7
8 1 Subsidies Price increase Towards a level playing field We need to stop subsidising But what if one player still is being subsidised? Non subsidized suppliers are being pushed out of the market and are not able to earn back their investments Scenario 2: new plant is needed, one government subsidises, the other does not Selective subsidization also affects the supply curve Supply curve FCR based pricing Price ( /six-day curie) P FCR Demand for 99 Mo R 1 R 2 R 3 R 4 Quantity (six-day curie) What if: R 4 gets subsidized by the govt? Supply curve with subsidies Price ( /six-day curie) P S Demand for 99 Mo Sub R 1 R 2 R 4 R 3 Quantity (six-day curie)! leading to inefficient market outcomes Demand and supply curve 99 Mo Price ( /six-day curie) P FCR # P Q FCR Q S FCR based supply curve Subsidized supply curve Quantity (six-day curie) Note: The supply curves in these figures are meant for illustrative purposes only, as they do not take into account Fixed costs 1 Individual players are hit 2 Individual new players that have entered the market at FCR levels are pushed out of the market Incentive to lower prices Players who are considering entering the market are hesitant because of selective subsidization Welfare loss Though smaller than when all are being subsidised 3 Transfer of welfare Though a smaller than when all are being subsidised 8
9 1 Subsidies Price increase Based on the self assessments, we seem to be on our way, but Progress is made in applying full-cost recovery. Results self assessment (2014) Argentina Australia Belgium Czech Republic Netherlands Poland Russia South Africa however subsidies are still being granted in some countries: Argentina s new plant is paid by government funds and at the current plant support is granted for capex and waste management Australian s government granted a loan to construct a new production plant and a waste processing plant, but the parties are now discussing if this loan can be waived off Belgian s new plant, MYRRHA, 40% funded by Belgian Ministries and currently Belgian Government pays for waste and security Czech republic s capital, overhead and decommissioning costs are not covered in the price Netherlands got a subsidy for the last refurbishment of the HFR. FCR is planned to be used in new PALLAS reactor Poland did not start yet, so assuming government funding. Intends to seek private funds for a new processing plant Russia applies its own FCR method for irradiations, processing and generator manufacturing South Africa does not grant financial support Not started Some progress made Significant progress made Fully implemented * For South Africa, Argentina, Belgium and Australia FCR progress applies for both reactor and processor Note: The self assessments are not entirely reliable/representative of countries progress towards FCR because there is no transparency in the methodology used to assess this (i.e., each country may interpret FCR differently and include different costs) 9
10 1 Subsidies Price increase still large incentives exists to subsidise. Security of Mo-99 supply in many countries is of public interest. Delay of investments could lead to governments stepping in The vicious circle of continued subsidy provision Lack of new investments Low prices Potential future shortage Govt. intervention (subsidies) Medical isotopes (e.g. 99 Mo) emerged as a by-product of the nuclear research market, thus they benefited from state aid - > resulting in low prices If low prices are maintained, the market becomes unattractive for investors, resulting in lack of investments Due to lack of investments (from the private sector), a potential supply shortage is predicted by the market A supply shortage would endanger security of supply thus govt. intervention occurs in the form of subsidies It is crucial that the market comes out of this vicious circle by breaking the low prices link -> start by moving to FCR New planned capacities are expected, but often delayed and decreased Projected capacity (6 day Ci-EOP x 10 6 / year) 4,0 3,5 3,0 2,5 2,0 1,5 1,0 0,5 0,0 Projections from Note: Projections, as reported in OECD-NEA reports 2010, 2012, 2014, 2016 FRM-II regarded as potential new capacity as they require adjustments to the reactor to be able to produce Actual capacity in 2010 derived from actual capacity in 2012 Source: OECD-NEA 2010, OECD-NEA updates 10
11 Subsidies 2 Price increase At a first glance, it seems to be easy to increase prices: Full Cost Recovery (FCR) levels at the reactor will have a limited impact (~1% increase) on the end price. So, no problem right? Prices per 6-day Curie 99 Mo across the supply chain Price increase from reactor (move to FCR) Selling price Easy? Easy? Easy? 99 Mo prices at Full Cost Recovery (FCR) levels will have limited impact on the end price Reactor Processor Generator Radio pharmacy Price increase towards FCR 20 (needed) ~6% increase ~5% increase ~1% increase Source: The supply of Medical isotopes: An economic study of the Molybdenum-99 supply chain, OECD (2010) Strategy& analysis based on input from interviews with stakeholders across the chain 11
12 Subsidies 2 Price increase But can the market increase prices? This depends on three economic forces:! Willingness to pay # Pass-trough in the chain If prices increase will the demand be lowered because the end users switch to alternatives? Or if different production techniques exist in the supply chain, will suppliers of the end product switch to other supply chains? Are end consumers of the product willing to pay more? Are there additional pressures on the system? Rising healthcare costs? Do the market dynamics allow pass-through of price increases along the supply chain? Are there inherent market characteristics that will cause resistance to any price changes? 12
13 Subsidies 2 Price increase From an economic viewpoint, there seems to be limited disciplining at present from downstream substitutes like PET. In developed markets, there might be higher disciplining from PET in the future Downstream substitutes analysis Parameter SPECT PET Imaging quality Technological trend Traditionally lower resolution but less expensive Towards hybrid SPECT/CT Traditionally better imaging quality than SPECT, yet more expensive Towards hybrid PET/CT Market size 26,200 (2015) 4,900 (2015) Market size trend (developed countries) Market size trend (emerging markets) Declining Rising Rising Not rising rapidly (due to higher cost) Tracer used Tc-99m Fludeoxyglucose (FDG) Number of procedures Using Tc-99m (2015): Using FDG (2015): 39,1 million 1 4,6 million 1 Cost of machine $ 400k - $ 600k $ 2 million Cost of medicine per procedure ~$ 68 ~$ Total number of procedures: 48 million (MEDRaysIntell 2015), less 2 million assumed for therapeutics; percentages are rounded Source: Strategy& analysis, Wikipedia, Zimmermann workshop 2016 The cost of SPECT machines (and scans) are much lower than the cost of PET. Therefore, PET currently does not seem to be a commercial substitute (no disciplining effect on prices). However, the time needed for performing a PET scan is lower. These efficiency gains are taken into account in the cost analysis, but it might lead to an advantage for PET scans. In developed markets, there might be higher disciplining from PET in the future because the number of PET procedures and new camera installations have grown faster than SPECT over the last 20 years, driven by better imaging quality of PET. But, quality improvements for SPECT are expected through software updates and by moving to hybrid SPECT/CT. In the emerging markets, PET is not expected to be chosen over SPECT in the near future, because PET cameras are more expensive as an initial investment and the most common isotope for PET (F-18) requires dense cyclotron network to produce generators. In the short run, a price increase should be possible 14
14 Subsidies 2 Price increase and at the upstream level, there is limited disciplining from alternative production technologies as they are not commercially viable or scalable at present Upstream substitutes analysis Parameter Nuclear research reactor Cyclotron reactor Tech. development Proven Mature, small scale Purity High Lower GMP approval OK Not yet Geographic constraints on market Number of plants needed to replace one reactor (of ~150 kci/yr) Global Local N/A Reactor based production is expected (globally) to remain the dominant supply route for Mo-99 because it is economically more efficient when compared to Cyclotrons Cyclotron production is not expected to compete on a large scale with reactors in the foreseeable future Other new technologies (e.g. SHINE, ASML reactor etc.) depend on unproven technology and success remains highly uncertain. But, if they become technically and commercially competitive in the future, there might be a higher disciplining effect on prices Half-time 66 hrs 6 hrs CAPEX requirement million 3-5 billion OPEX 25 million ~ 1 billion Production cost ~ 15 per Tc-99 dose ~ 70 per Tc-99 dose In the short run, a price increase should be possible Source: Strategy& analysis, RRFM Conference 2016, ANSTO, OECD-NEA 2010, Wikipedia, Zimmermann workshop
15 Subsidies 2 Price increase Because of rising healthcare costs, there is strong drive towards cost reduction at the insurance companies. So, even if the willingness to pay is high at end-user level, insurers might oppose price increases Growth of health expenditure ( /capita) CAGR +4% Europe Patients/ Hospitals Insurance companies/ Governments (health care schemes) CAGR 2000 CAGR +3% +5% 2016 Japan United States Willingness to pay at the end-user level is believed to be high because of the benefits from diagnostic scans (hospitals can provide better health care based on a good diagnosis and patients have a better chance of recovery) but with rising healthcare costs, governments and/or insurers might oppose price increases depending on the market structure and health care schemes in different countries Source: Strategy& analysis using OECD data (2017) 1 Europe here refers to the Euro area. Therefore, UK is not included. Pictures courtesy: Nounproject.com 14
16 Subsidies 2 Price increase and the ability to transfer price along the chain is also low at the Generator manufacturer and radiopharmacy level Research Reactors Processors Generator Manufacturers Radiopharmacies Ability to transfer price increase High High Low Low OPAL LVR-15 HFR Curium ANSTO Health ANTSO Health NTP GE Healthcare Lantheus North America Market coverage MARIA SAFARI BR-2 Currently 6 serving global market NTP IRE Currently 4 serving global market Curium Currently 5 serving globally; Curium might have market power Europe Rest of the world Largest market: US, with Cardinal having 60% market share Capacity restrictions Medium High Low Low Ease of switching suppliers Low (Due to transportation constraints of targets, it is a local market with very few target suppliers) Low (takes time due to logistics, licensing & contract related issues) High (Generators can source globally, and Curium might have high bargaining power) High (Radiopharmacies source globally, but face pressure from healthcare market) Source: Strategy& analysis based on OECD-NEA data (2016), OECD-NEA updates; Market coverage percentages for reactors and processors are based on capacity 15
17 How can governments help? Policy instruments to facilitate the implementation of FCR (1/2) Instrument Creates a level playing field? Helps in absorbing price increases? Supply chain participants impacted Who can enforce it? State Aid regulation enforcement in the EU - Investigation by European Commission to ensure State aid complies with EU rules Everyone (but mainly noncompliant Reactors & Processors) within EU European Commission (EC) Anti-dumping* measures ad valorem duty, or specific duties (paid by the importer) or price undertakings (company offers to sell at a minimum price) Legal obligation for FCR to include all costs within the price Earmarking subsidies for research & performing regular audits for proof Auditing players along the chain for FCR compliance Government regulation Processors and Generators outside EU Reactors and Processors (easier to implement if they are state owned) Reactors that receive subsidies, to avoid cross subsidies All Reactors, Processors & Generators European Commission (EC) and national governments National govts (with no state aid regulation) EC and national governments EC and national governments 16
18 How can governments help? Policy instruments to facilitate the implementation of FCR (2/2) Instrument Creates a level playing field? Helps in absorbing price increases? Supply chain participants impacted Who can enforce it? Anti-trust policy Government investigation to prevent abuse of dominant position in the market or the existence of cartels All supply chain participants European Commission (EC) and national competition authorities Split the price component related to nuclear isotopes within the diagnostic cost Government health care regulation Radiopharmacies, Insurers and Hospitals National governments & healthcare systems FCR Label for 99 Mo (combined with audits to ensure FCR compliance) Lobbying for FCR-based absorption of price increases downstream Possibility to renegotiate prices in contracts Between market players Reactors, processors and generators Everyone (since entire chain needs to be FCR compliant for the label) Radiopharmacies, Insurers and Hospitals National regulators, competition authorities National governments Health ministries within each nation 17
19 Closing statement and contact details The goal should not be to stop at FCR, but to build a sustainable market jan.willem.velthuijsen@pwc.com Tel.:
20 Supporting slides: policy instruments 19
21 Policy instruments to facilitate the implementation of FCR by creating a level-playing field Instrument State Aid regulation enforcement in the EU - Investigation by European Commission to ensure State aid complies with EU rules Anti-dumping* measures ad valorem duty, or specific duties (paid by the importer) or price undertakings (company offers to sell at a minimum price) Legal obligation for FCR to include all costs within the price Earmarking subsidies for research & performing regular audits for proof Auditing players along the chain for FCR compliance Government regulation Description Treaty on the Functioning of the EU generally prohibits State Aid unless it is justified by reasons of general economic development. 1) Intervention by the State or through State resources which can take a variety of forms (e.g. grants, interest and tax reliefs, guarantees, government holdings of all or part of a company, or providing goods and services on preferential terms, etc.); 2) The intervention gives the recipient an advantage on a selective basis, for example to specific companies or industry sectors, or to companies located in specific regions 3) Competition has been or may be distorted; 4) the intervention is likely to affect trade between Member States. 1) A company is dumping if it is exporting a product to the EU at prices lower than the normal value of the product (the domestic prices of the product or the cost of production) on its own domestic market. 2) A material injury must have be suffered by the Community industry (causally linked). 3) Imposition of measures is not against the Community interest. All market parties within the 99 Mo supply chain should be legally obliged to set their prices at FCR levels. This is claimed to have been done in Australia. But, implementing this will be a challenge because it needs to be proved that the market functions more efficiently if this is done, and that end-consumers are expected to benefit from it. All government subsidies provided to Nuclear reactors should be earmarked for specific research activities, and this should be audited by an independent party every year to prevent any cross-subsidization between research & medical isotope production Audit of cost structures and allocation of costs to 99 Mo production, prices charged (include the costs?) and subsidies received (specific subsidies for 99 Mo and for other activities) 20
22 Policy instruments to facilitate the absorption of FCR-based price increases across the supply chain Instrument Anti-trust policy Government investigation to prevent abuse of dominant position in the market or the existence of cartels Split the price component related to nuclear isotopes within the diagnostic cost Government health care regulation FCR Label for 99 Mo (combined with audits to ensure FCR compliance) Description Check and prevent the creation of horizontal agreements (between actual or potential competitors operating at the same level of the supply chain) and vertical agreements (between firms operating at different levels, i.e. agreement between a manufacturer and its distributor). Check and prevent all 99 Mo supply chain participants from abusing market power (by charging unfair prices, by limiting production, or by refusing to innovate) Separate/unbundle the price component related to 99 Mo/ 99m Tc within the final price of SPECT/PET procedure, in order to track the development of the costs Generator manfacturers can proof to their customers (radiopharmacies) that they sources the 99 Mo from processors/reactors that are FCR compliant. Lobbying for FCR-based absorption of price increases downstream Possibility to renegotiate prices in contracts - Between market players All governments that are committed and moving towards FCR implementation within their value chain, should drive the absorption of FCR-based price increases downstream by lobbying within the healthcare system Contracts between different players across the supply chain are currently long-term based. These should be flexible for renegotiation of prices. 21
The Economics of Reactor Produced Mo-99
The Economics of Reactor Produced Mo-99 Francois Couillard CANM, April 21, 2017 Disclosures I am a GE shareholder The CAMRT receives funding for Continuing Education and/or its annual conference from Curium,
More informationA Supply and Demand Update of the Molybdenum-99 Market
August 2012 A Supply and Demand Update of the Molybdenum-99 Market Introduction Medical diagnostic imaging techniques using technetium-99m account for roughly 80% of all nuclear medicine procedures, representing
More informationHEU MINIMISATION CHALLENGES. THE SUPPLY OF THE MEDICAL ISOTOPE 99-MOLYBDENUM/99m- TECHNETIUM
HEU MINIMISATION CHALLENGES THE SUPPLY OF THE MEDICAL ISOTOPE 99-MOLYBDENUM/99m- TECHNETIUM Chad Westmacott Nuclear Development Division OECD Nuclear Energy Agency 99m Tc is the decay product of 99 Mo
More informationSupply of Medical Radioisotopes. IPET Vienna October 10, Kevin Charlton Nuclear Development Division OECD/NEA
Supply of Medical Radioisotopes IPET 2015 - Vienna October 10, 2015 Kevin Charlton Nuclear Development Division OECD/NEA Kevin Charlton Senior Analyst - Nuclear Energy Agency (NEA) of the OECD Secretariat
More informationCORAR Council on Radionuclides and Radiopharmaceuticals, Inc.
RAR Council on Radionuclides and Radiopharmaceuticals, Inc. Understanding the Radiopharmaceutical Drug Supply Problem: Session 1 Michael J. Guastella, MS MBA Executive Director Council on Radionuclides
More informationThe Current State of Mo-99 Supply and the Conversion to LEU
The Current State of Mo-99 Supply and the Conversion to LEU Target Audience: Pharmacists ACPE#: 0202-0000-18-078-L04-P Activity Type: Knowledge-based Target Audience: ACPE#: Activity Type: 22 Disclosures
More informationHigh-Level Group on the Security of Supply of Medical Radioisotopes
Unclassified NEA/SEN/HLGMR(2014)2 NEA/SEN/HLGMR(2014)2 Unclassified Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development 22-Apr-2014 English
More informationWorld status on reactor and cyclotron radioisotope production
World status on reactor and cyclotron radioisotope production Richard Zimmermann Chrysalium Consulting Mechelen, May 11, 2017 Global trends 2017 Second wave of growth with 177 Lu-Lutathera 2014 The therapeutic
More informationReactor Schedule Coordination for Molybdenum-99 Supply Reliability
Schedule Coordination for Molybdenum-99 Supply Reliability Bernard PONSARD Co-Chairman AIPES Security of Supply Working Group The National Academies NAS-RAS Joint Mo-99 Symposium Opportunities and Approaches
More informationThe Future of LEU in the Global Mo-99 Supply Chain
The Future of LEU in the Global Mo-99 Supply Chain Ira Goldman, Director, Strategic Product Supply High Country Nuclear Medicine Conference Vail Marriott March 2013 NRU HFR BR2 Osiris LVR-15 LMI Mo-99
More informationHigh-Level Group on the Security of Supply of Medical Radioisotopes
Unclassified NEA/SEN/HLGMR(2016)4 NEA/SEN/HLGMR(2016)4 Unclassified Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development 13-Jul-2016 English
More informationAustralia s unique leadership role
The Global Mo-99 Crisis: s unique leadership role November 09 While most of the world has focused on the global financial crisis, another serious predicament, with enormous ramifications for the world
More informationThe Supply of Medical
Nuclear Development NEA/SEN/HLGMR(2017)5 December 2017 www.oecd-nea.org The Supply of Medical Radioisotopes Results from the Third Self-assessment of the Global Mo-99/Tc-99m Supply Chain Acknowledgements
More informationGlobal Threat Reduction Initiative
U.S. DEPARTMENT OF ENERGY Global Threat Reduction Initiative Implementing the American Medical Isotopes Production Act OSTP Mo-99 Stakeholder s Meeting December 2013 The American Medical Isotopes Production
More informationHigh-Level Group on the Security of Supply of Medical Radioisotopes
Unclassified NEA/SEN/HLGMR(2013)7 NEA/SEN/HLGMR(2013)7 Unclassified Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development 04-Sep-2013 English
More informationStatus of Mo-99 Supply and New Developments
Status of Mo-99 Supply and New Developments Joao Alberto Osso Junior Head, Radioisotope Products and Radiation Technology Section 06 October 2015 International Atomic Energy Agency The Mandate The Agency
More informationRadiopharmaceuticals overview of requirements
Radiopharmaceuticals overview of requirements Did you know? That Australia has a research nuclear reactor producing nuclear medicine 1 in 2 Australians will receive some kind of nuclear medicine in their
More informationGuidance Document. Full-cost Recovery for Molybdenum-99 Irradiation Services: Methodology and Implementation
Nuclear Development NEA/SEN/HLGMR(2012)9 February 2012 www.oecd-nea.org Guidance Document Full-cost Recovery for Molybdenum-99 Irradiation Services: Methodology and Implementation N U C L E A R E N E R
More informationThe medical isotope crisis
The medical isotope crisis Introduction Last year saw a major worldwide crisis in the availability of medical radioisotopes. More specifically in the production of Mo-99/Tc-99m generators for diagnostic
More informationMedical isotope production in Australia:
Medical isotope production in Australia: Should we be using reactor based or cyclotron technology? 15 th January 2016 Dr Margaret Beavis MBBS FRACGP MPH Medical Association for Prevention of War, Australia
More informationThe Supply of Medical Radioisotopes
Nuclear Development ISBN 978-92-64-99149-1 The Supply of Medical Radioisotopes An Economic Study of the Molybdenum-99 Supply Chain OECD 2010 NEA No. 6967 NUCLEAR ENERGY AGENCY ORGANISATION FOR ECONOMIC
More informationThe Supply of Medical
Nuclear Development 2010 The Supply of Medical Radioisotopes An Economic Study of the Molybdenum-99 Supply Chain: Summary N U C L E A R E N E R G Y A G E N C Y Nuclear Development ISBN 978-92-64-99150-7
More informationThe 99 Mo Supply Chain for Nuclear Medicine
for Nuclear Medicine Department of Electrical and Computer Engineering University of Hartford BE 281 - BE 381 Biomedical Engineering Seminar I and II November 13, 2012 Nuclear Medicine: Meeting Patient
More informationReport on the. Security of Supply. of Medical Radioisotopes. Euratom Supply Agency. Energy
Extract from the Karlsruhe Nuclide Chart, 8th Edition (2012) Report on the Security of Supply of Medical Radioisotopes Euratom Supply Agency Energy REPORT TO THE EUROPEAN COMMISSION on activities following
More informationREPORT FROM THE COMMISSION TO THE COUNCIL AND THE EUROPEAN PARLIAMENT. Operation of the High Flux Reactor in the years {SWD(2018) 46 final}
EUROPEAN COMMISSION Brussels, 27.2.2018 COM(2018) 76 final REPORT FROM THE COMMISSION TO THE COUNCIL AND THE EUROPEAN PARLIAMENT Operation of the High Flux Reactor in the years 2014-15 {SWD(2018) 46 final}
More informationANSTO Nuclear Medicine: Reliable and Timely Mo-99 Supply Globally
Presentation 8 Session 3 ANSTO Nuclear Medicine: Reliable and Timely Mo-99 Supply Globally Jayne Senior General Manager, ANSTO Nuclear Medicine Pty Ltd (ANM) Biography Jayne Senior is General Manager for
More informationMedical Isotope Production by Electron Accelerators. R.S. Orr University of Toronto
Medical Isotope Production by Electron Accelerators R.S. Orr University of Toronto Power Reactor Uranium Fission Chain reaction neutrons ANSTO's Open Pool Australian Lightwater (OPAL) Reactor is a state-of-the-art
More informationIAEA assistance in RI production and supply: 99 Mo case
IAEA assistance in RI production and supply: 99 Mo case Joao Alberto Osso Junior Head, Radioisotope Products and Radiation Technology Section NAPC/NA/IAEA The IAEA Mandate The Agency shall seek to accelerate
More informationProducing Molybdenum-99 in CANDU Reactors. Jerry M Cuttler Cuttler & Associates Inc. Abstract
31 st Annual Conference of the Canadian Nuclear Society, Montréal, Québec, 2010 May 24-27 Producing Molybdenum-99 in CANDU Reactors Jerry M Cuttler Cuttler & Associates Inc Abstract This paper discusses
More informationWorking Group 4 (WG4) Capacity and Infrastructure Development. July, 2014
Working Group 4 (WG4) Capacity and Infrastructure Development July, 2014 1. Overview Radionuclides are used in nuclear medicine for the diagnosis and treatment of various diseases, such as cancer, cardiovascular
More informationPerma-Fix Medical. Investor Presentation January 2016
Perma-Fix Medical Investor Presentation January 2016 1 Safe Harbor Certain statements contained within this presentation may be deemed forward-looking statements within the meaning of Section 27A of the
More informationInternational Perspective on non-heu Mo-99 Production
International Perspective on non-heu Mo-99 Production International Symposium on HEU Minimisation Vienna 23-25 January 2012 Dr Adrian Paterson Michael Druce Australian Nuclear Science and Technology Organisation
More informationMeeting the moly-99 challenge
Greg Piefer, founder and CEO of SHINE Medical Technologies, aims to begin production of Mo-99 at the company s Janesville, Wis., campus in 2020. Photo: SHINE Meeting the moly-99 challenge In the race to
More informationPlastics Machinery Manufacturers Association of India. Make in India Workshop 29 th Dec 2014
Plastics Machinery Manufacturers Association of India Make in India Workshop 29 th Dec 2014 Starting Point (PPM) Overview Plastics Machinery Industry Sector is relatively young in our country having come
More informationChapter 7 Energy-Related Carbon Dioxide Emissions
Chapter 7 Energy-Related Carbon Dioxide Emissions In the coming decades, actions to limit greenhouse gas emissions could affect patterns of energy use around the world and alter the level and composition
More informationGovernment Intervention
Government Intervention Taxes - Aim of imposing indirect taxes: the government does such spending in order to raise tax revenues and to internalize externalities, to achieve the optimum level of output.
More informationThreats and Opportunities for the Dutch Agribusiness Dr. Siemen van Berkum LEI, Wageningen UR
Paper contribution to the EBN seminar Competitiveness of Agriculture in Central and Eastern Europe over the next 25 Years. Likely consequences for the Dutch agribusiness The Hague, 26 May 2005 Threats
More informationGlobal Threat Reduction Initiative
U.S. DEPARTMENT OF ENERGY Global Threat Reduction Initiative Establishing Reliable Supplies of Mo-99 Produced Without HEU Dr. Parrish Staples September 27, 2011 GTRI Mission & Program Goals Convert Remove
More informationUranium: Critical to a Clean Energy Future
Uranium: Critical to a Clean Energy Future 2015 ATSE Eminent Speaker Series Vanessa Guthrie August 2015 Why talk about uranium? 2 2 How safe is uranium and nuclear? Can Fukushima happen again? Can Australian
More informationCurrent challenges and opportunities in energy and uncertain futures
www.polinares.eu Current challenges and opportunities in energy and uncertain futures ACCESSING OIL, GAS AND MINERALS IN A CHANGING WORLD From the Final Conference of the EU research project POLINARES:
More informationNuclear Power Economics and Markets
Nuclear Power Economics and Markets IBC - Decommissioning of Nuclear Reactors & Materials 29 30 September 2014; Miami, Florida Edward Kee Disclaimer The NECG slides that follow are not a complete record
More informationMedical isotopes. in a European context. Global importance and opportunities for the Netherlands.
Medical isotopes Global importance and opportunities for the Netherlands in a European context www.nuclearnetherlands.com Medical isotopes, global importance and opportunities for the Netherlands is a
More informationNUMBERS AT A GLANCE. EU Member States have implemented. packaging waste policies
Factsheet Extended Producer Responsibility (EPR) for used Packaging The EU Packaging and Packaging Waste Directive (PPWD) provides a longstanding and successful legislative framework, enabling continuous
More informationCHALLENGES OF GLOBAL CLINICAL TRIAL SUPPLY SOURCING SOME SPECIFICS FOR EMERGING MARKETS
Clinical Trial Supply 28 th 29 th October 2014 Princeton, NJ - USA CHALLENGES OF GLOBAL CLINICAL TRIAL SUPPLY SOURCING SOME SPECIFICS FOR EMERGING MARKETS 1 Agenda The challenges associated with various
More informationThe Anti-monopoly Commission of the State Council. Anti-monopoly Guideline on Abuse of Intellectual Property Rights.
The Anti-monopoly Commission of the State Council Anti-monopoly Guideline on Abuse of Intellectual Property Rights (Exposure Draft) (December 31, 2015) Preamble Anti-monopoly and intellectual property
More informationGlobal Threat Reduction Initiative
U.S. DEPARTMENT OF ENERGY Global Threat Reduction Initiative Progress Towards Eliminating Use of Highly Enriched Uranium in Medical Isotope Production and Research and Test Reactor Fuel and Repatriation
More informationENSURING RELIABLE MEDICAL ISOTOPE SUPPLY
ENSURING RELIABLE MEDICAL ISOTOPE SUPPLY Hedges, K. 1, and Malkoske G. 2 1 Atomic Energy of Canada Limited, Mississauga, Ontario, Canada 2 MDS Nordion, Ottawa, Ontario, Canada 1. Introduction This paper
More informationLeadership Presentation at ETEC Nuclear Suppliers Workshop. Coquí Pharma. Oak Ridge, TN 6-7 September, 2017
Leadership Presentation at ETEC Nuclear Suppliers Workshop Coquí Pharma Oak Ridge, TN 6-7 September, 2017 Carmen I. Bigles Chief Executive Officer Introduction Medicine is a science of uncertainty and
More informationChapter 9. The Instruments of Trade Policy
Chapter 9 The Instruments of Trade Policy Preview Partial equilibrium analysis of tariffs in a single industry: supply, demand, and trade Costs and benefits of tariffs Export subsidies Import quotas Voluntary
More informationOverview of DH pricing and regulation in Europe
Overview of DH pricing and regulation in Europe Riga, December 4 th 2012 Fortum, Heat Division Harri-Pekka Korhonen 1 District heating regulation regimes vary across Europe Should EU have a role to drive
More informationEUROPEN position on Extended Producer Responsibility for post-consumer packaging in the EU
EUROPEN position on Extended Producer Responsibility for post-consumer packaging in the EU THE POLICY CONTEXT Extended Producer Responsibility (EPR) is a policy approach 1 which obliges producers to take
More informationEUROPEN position on Extended Producer Responsibility for post-consumer packaging in the EU
EUROPEN position on Extended Producer Responsibility for post-consumer packaging in the EU THE POLICY CONTEXT Extended Producer Responsibility (EPR) is a policy approach 1 which obliges producers to take
More informationLeadership Presentation at Joint US & Russian Academies of Science Conference. Coquí Pharma. Vienna, AUSTRIA 17 July, Carmen I.
Leadership Presentation at Joint US & Russian Academies of Science Conference Coquí Pharma Vienna, AUSTRIA 17 July, 2017 Carmen I. Bigles (CEO) Introduction Medicine is a science of uncertainty and an
More informationEssence of the suggestion
Essence of the suggestion WTO Members, including Japan, are currently implementing agricultural policy reform under the present basic framework of rules and disciplines on domestic support. This framework
More informationThe Drug Importation Debate: An Economic Perspective
The Drug Importation Debate: An Economic Perspective Patricia M. Danzon PhD The Wharton School University of Pennsylvania http://hc.wharton.upenn.edu/danzon/index.htm Effects of Legalizing Drug Importation
More informationRail freight and development
Rail freight and development Transport Forum & Learning Week Paul Amos: Transport Advisor World Bank Washington, March 2007 0 Contents World Bank and railways: overview Financing sources for public railways
More informationLead the way. Molecular Imaging. GE Healthcare. imagination at work
2010 General Electric Company All rights reserved. General Electric Company reserves the right to make changes in specifications and features shown herein, or discontinue the product described at any time
More informationThe European Market for Woody Biomass Supply and Demand Drivers and Trends
The European Market for Woody Biomass Supply and Demand Drivers and Trends Who Owns the Forest Conference Portland; 17 September 2015 Petri Lehtonen, Senior Partner, Indufor Oy 17 September 2015 Indufor
More informationAS Economics. Producer Subsidies. tutor2u Supporting Teachers: Inspiring Students. Economics Revision Focus: 2004
Supporting Teachers: Inspiring Students Economics Revision Focus: 2004 AS Economics tutor2u (www.tutor2u.net) is the leading free online resource for Economics, Business Studies, ICT and Politics. Don
More informationWater supply and sanitation in Latin America (moving toward sustainability following two decades of reforms)
Water supply and sanitation in Latin America (moving toward sustainability following two decades of reforms) By Andrei S. Jouravlev Economic Affairs Officer, Natural Resources and Infrastructure Division,
More informationFuture Supply of Medical Radioisotopes for the UK Report 2014
Future Supply of Medical Radioisotopes for the UK Report 2014 Report prepared by: British Nuclear Medicine Society and Science & Technology Facilities Council. December 2014 1 Preface Technetium-99m (
More informationPlastics Processing Machinery (PPM) Overview
Plastics Processing Machinery (PPM) Overview Plastics Machinery Market is Approx Rs. 4,000 Crores. Domestic production is Approx Rs. 2,400 Crores. Sector employs approx 1.20 Lakh (Direct + Indirect) people
More informationEU trade policy for mining and metals
JOINT STUDY GROUPS' SEMINAR EU trade policy for mining and metals Lisbon, 22.04.2015 Caroline Boeshertz, European Commission, DG Trade Outline Raw materials and trade global challenges The EU Trade policy
More informationStandard Merger Notification Form Information Requirements Part 3: Markets
Stard Merger Notification Form Information Requirements Part 3: Markets DISCLAIMER: This publication is a compilation of information received from national competition authorities of the European Union
More informationTypes of abuses and anti- competitive agreements in regulated sectors
Types of abuses and anti- competitive agreements in regulated sectors Zagreb 16 March 2006 Tasneem Azad, DotEcon Ltd DotEcon Ltd, 17 Welbeck Street, London www.dotecon.com Structure of presentation Abusive
More informationSAVING OIL IN A HURRY - DEMAND MANAGEMENT MEASURES
SAVING OIL IN A HURRY - DEMAND MANAGEMENT MEASURES Transport, Energy Efficiency & Behaviour Workshop, May 2016 Martin Young, Head of Emergency Policy Division Context - Establishment of IEA IEA established
More informationPromoting Competition
The Business Growth Agenda Promoting Competition Part of Building Innovation August 2017 Ministers Foreword The Business Growth Agenda () sets out the Government s work to build a productive and competitive
More informationThe OECD The Nuclear Energy Agency
The OECD The Nuclear Energy Agency Janice Dunn Lee OECD/NEA Deputy Director-General WNU Summer Institute July 14, 2011 1 Overview The OECD/NEA The Work of the NEA The NEA and Other International Organisations
More informationREPORT FROM THE COMMISSION TO THE COUNCIL AND THE EUROPEAN PARLIAMENT. Operation of the High Flux Reactor in the period
EUROPEAN COMMISSION Brussels, 5.4.2016 COM(2016) 170 final REPORT FROM THE COMMISSION TO THE COUNCIL AND THE EUROPEAN PARLIAMENT Operation of the High Flux Reactor in the period 2012-2013 {SWD(2016) 101
More informationDriving Innovation through Finance Presented by Paul PJ McElroy Manufacturing in America March 14-15, 2018
Driving Innovation through Finance Presented by Paul PJ McElroy Manufacturing in America March 14-15, 2018 Before we start A Penny for Your Thoughts At the end of the session, share your feedback via MiA
More informationEnergy & Climate Change ENYGF 2015
Energy & Climate Change ENYGF 2015 Ellina Levina Environment & Climate Change Unit Sustainable Energy Policy and Technology, IEA 22 June 2015 29 Member Countries: Australia, Japan, Korea, New Zealand,
More informationNuclear Power Development in Europe: Rosatom perspective
ROSATOM Nuclear Power Development in Europe: Rosatom perspective Alexey Kalinin Head, International Business, Rosatom CEO, Rusatom Overseas Platts 7 th Annual European Nuclear Conference June 25-26, 2012
More informationThe Threat Posed by HEU, and Legislation to Reduce Bomb- Grade Uranium Commerce
The Threat Posed by HEU, and Legislation to Reduce Bomb- Grade Uranium Commerce Alan J. Kuperman, Ph.D. Associate Professor, LBJ School of Public Affairs; and Director, Nuclear Proliferation Prevention
More informationIndex. Africa See Central Africa; East Africa; Southern Africa; West Africa
Index Page numbers followed by n. and a number refer to numbered notes. Page numbers followed by t or f refer to tables or figures, respectively. Page numbers in italic refer to boxed text. A Africa See
More informationCertification in Central and Eastern Europe
Certification in Central and Eastern Europe Timber Regulation Enforcement Exchange Vienna, 16 September 2015 Dirk Teegelbekkers General Secretary PEFC Germany www.pefc.org www.pefc.org Overview Introduction
More informationIn the domestic market of the EU a modest growth of dairy consumption can be expected, mainly in the cheese sector.
EU Dairy Markets, Situation and Outlook, June 2017 by Erhard Richarts, Dairy Market Consultant, Chairman of IFE (Institut für Ernährungs-wirtschaft e. V., Kiel) Highlights: Special report produced for
More informationReplies to: Questions for the Hearing on the completion of the internal energy market
/HLJK+$1&+(5 Catholic University Brabant, Tilburg Replies to: Questions for the Hearing on the completion of the internal energy market 1.) Questions concerning both the directive on common rules for the
More informationUPS Response to the ERGP 2019 Work Program September 2018
UPS Response to the ERGP 2019 Work Program September 2018 We would like to thank the ERGP for the opportunity to provide input on their 2019 work program and we would also like to congratulate you on the
More informationHow? Establish a global power sector carbon budget
What? Bend the curve in global emissions within a decade of Copenhagen How? Establish a global power sector carbon budget 1. Introduction A key criteria for a global climate change deal in Copenhagen in
More informationSteel, Industrial Policy, and Economic Performance. Bruce Blonigen University of Oregon and NBER
Steel, Industrial Policy, and Economic Performance Bruce Blonigen University of Oregon and NBER Motivation The effects of Industrial Policy (IP) are controversial IP often consists of a multitude of programs,
More informationEfficiency of Market Equilibrium 3.1 SAMPLE
Castle Got the answer? Be the first to stand with your group s flag. Market Equilibrium 3.1 Question 1: Define market equilibrium. Got it correct? MAKE or BREAK a castle, yours or any other group s. The
More informationRussian energy and CO 2 emission prospects: evidence from domestic analyses and international comparisons
Russian energy and CO 2 emission prospects: evidence from domestic analyses and international comparisons By Michael Grubb March 2004 Visiting Professor, Climate Change and Energy Policy, Imperial College
More informationJoven Liew Jia Wen Industrial Economics I Notes. What is competition?
Industrial Economics I Notes What is competition? Competition in markets is generally considered a good thing (welfare economics) Competition authorities look at whether change in market structure or firm
More informationENDING HEU USE IN MEDICAL ISOTOPE PRODUCTION: OPTIONS FOR RUSSIAN-U.S. COOPERATION* Anton Khlopkov and Miles Pomper with Valeriya Chekina**
February 24, 2014 ENDING HEU USE IN MEDICAL ISOTOPE PRODUCTION: OPTIONS FOR RUSSIAN-U.S. COOPERATION* Anton Khlopkov and Miles Pomper with Valeriya Chekina** Great progress has been achieved in recent
More informationTerms of Reference and Outline Work Programme
Terms of Reference and Outline Work Programme High Level Group on the Security of Supply of Medical Radioisotopes (HLG-MR) Under the Auspices of the OECD Nuclear Energy Agency Background On January 29-30,
More informationIndian Pharmaceutical Industry. January 2018
Indian Pharmaceutical Industry January 2018 Introduction The pharmaceutical Industry around the world is one of the fastest growing industries and a major contributor to the world economy. 2020 55 1400
More informationThe Future of Consumer Health Care
The Future of Consumer Health Care Coming Together To Lead The Consumer Health Care Industry 2 Creating a New Business Model in Consumer Health Care 3 Serve More Consumers In More Parts of the World, More
More informationIFC s Approach to Climate Change in the Electricity Sector
IFC s Approach to Climate Change in the Electricity Sector Oct 2008 Contents/Agenda 1. Climate Change, Economic Development, & the Electricity Sector 2. Mitigating Climate Change: Efficiency, Technology,
More informationCompetitive Neutrality Project UNCTAD RPP Meeting July Project leader: Deborah Healey
Competitive Neutrality Project UNCTAD RPP Meeting July 7 2013 Project leader: Deborah Healey The views expressed are those of the author and do not necessarily reflect the views of UNCTAD What is competitive
More informationGlobal Forum on Competition
Unclassified DAF/COMP/GF/WD(2014)51 DAF/COMP/GF/WD(2014)51 Unclassified Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development 14-Feb-2014 English
More informationS A Fruit & Vegetable Canning Industry
S A Fruit & Vegetable Canning Industry Presentation: Parliamentary Portfolio Committee: Trade & Industry - Revised IPAP: 2010/11 to 2012/13-05 March 2010 Introduction: Opening & Welcome Industry Delegation:
More informationChairman s Recap of Day 1. David Brennan, Head of Cargo Safety and Standards, IATA
DANGEROUS GOODS Chairman s Recap of Day 1 David Brennan, Head of Cargo Safety and Standards, IATA Keynote: Radioactive Materials N. Ramamoorthy, Director, Division of Physical and Chemical Sciences, IAEA
More informationSouth African nuclear industry overview Van Zyl de Villiers R&D Division Necsa
South African nuclear industry overview Van Zyl de Villiers R&D Division Necsa ASME Nuclear Codes and Standards Workshop 7 October 2008 Contents South African energy challenges South African Nuclear Energy
More informationImpact of MRCT after ICH E17 fully implement -Industry perspective-
Impact of MRCT after ICH E17 fully implement -Industry perspective- 5th Joint Conference of Taiwan and Japan on Medical Products Regulation December 1st, 2017 Chikara Kikuchi Vice-Chairperson, Drug Evaluation
More informationDEMAND AND SUPPLY. Chapter 3. Principles of Macroeconomics by OpenStax College is licensed under a Creative Commons Attribution 3.
DEMAND AND SUPPLY Chapter 3 Principles of Macroeconomics by OpenStax College is licensed under a Creative Commons Attribution 3.0 Unported License Demand for Goods and Services Demand refers to the amount
More informationSTX Services Environmental Brokerage. Amsterdam, July 2014 Max van Meer - Managing Director STX Services
STX Services Environmental Brokerage Amsterdam, July 2014 Max van Meer - Managing Director STX Services STX Services Agenda Introduction to STX Services Feed-in tariffs versus market based mechanisms Examples
More informationAGRICULTURAL TRADE AND ITS IMPORTANCE
AGRICULTURAL TRADE AND ITS IMPORTANCE 1. SOME HISTORICAL REFLECTIONS Since the founding of the Common Agricultural Policy (CAP) in 1959, one of the objectives was to increase productivity and the volume
More informationDr. Fatih BIROL IEA Chief Economist Tokyo, 17 February 2015
Dr. Fatih BIROL IEA Chief Economist Tokyo, 17 February 2015 Signs of stress in the global energy system Current calm in markets should not disguise difficult road ahead Turmoil in the Middle East raises
More informationThe EU Trade Policy and Raw Materials
Ref. Ares(2014)1000231-31/03/2014 Raw Materials Diplomacy Event The EU Trade Policy and Raw Materials Lima, Peru 10-11.03.2014 Caroline BOESHERTZ, European Commission, DG Trade Agenda Raw materials and
More informationYou know the destination. We know the way.
You know the destination. We know the way. AGES Your partner for pathbreaking toll and vignette systems in Europe If you would like to head for new horizons as far toll and vignette systems are concerned,
More information